(Q54506148)

English

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

author name string

E Alba

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

L Calvo

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

J Albanell

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

J R De la Haba

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

A Arcusa Lanza

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

J I Chacon

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

P Sanchez-Rovira

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

A Plazaola

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

J A Lopez Garcia-Asenjo

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

B Bermejo

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

E Carrasco

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

GEICAM

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

publication date

6 June 2012

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

3069-3074

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Molecular portraits of human breast tumours

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

The molecular portraits of breast tumors are conserved across microarray platforms

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Breast cancer classification and prognosis based on gene expression profiles from a population-based study

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Common markers of proliferation.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Are we HER-ting for innovation in neoadjuvant breast cancer trial design?

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Cytotoxic and antiproliferative activity of the single agent epirubicin versus epirubicin plus tamoxifen as primary chemotherapy in human breast cancer: a single-institution phase III trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Neoadjuvant endocrine therapy for breast cancer: past, present and future

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Phase II Trial of Anastrozole Plus Goserelin in the Treatment of Hormone Receptor–Positive, Metastatic Carcinoma of the Breast in Premenopausal Women

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

HER2 and Response to Paclitaxel in Node-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS132

21 January 2018

Identifiers

10.1093/ANNONC/MDS132

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22674146%20AND%20SRC:MED&resulttype=core&format=json

3 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54506148&oldid=1236672132"